EP. 1: The Targeted Pulse: New Approvals Are Advancing the Field, and the MARIPOSA Trial Continues to Deliver
The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.
